Vismodegib and Enzalutamide Recommended for EU ApprovalVismodegib and Enzalutamide Recommended for EU Approval
In addition, 2 generic cancer drugs have been recommended for approval in Europe: the oral agents capecitabine and imatinib. International Approvals (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 29, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
Imatinib-Resistant Patients With Chronic Myeloid LeukemiaImatinib-Resistant Patients With Chronic Myeloid Leukemia
What's the best plan for patients with CML who don't respond to imatinib? Therapeutic Advances in Hematology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 26, 2013 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Rajasthan govt to give free cancer drugs
In a major relief for blood cancer patients, the state's health department is all set to provide Imatinib tablets ("magic bullet" tablets) free of cost to them. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 21, 2013 Category: Pharmaceuticals Source Type: news
Chronic Fatigue Limits Quality of Life in Imatinib-Treated CML Patients
A study of patients with chronic myeloid leukemia treated with imatinib found that chronic fatigue is the major factor that limits health-related quality of life. (Source: Cancer Network)
Source: Cancer Network - April 17, 2013 Category: Cancer & Oncology Source Type: news
Doctors win $500,000 Albany Prize for Gleevec, cancer research
ALBANY, N.Y., April 17 (UPI) -- The Albany Medical Center Prize in Medicine and Biomedical Research went to three physicians who altered the course of cancer research, New York officials say. (Source: Health News - UPI.com)
Source: Health News - UPI.com - April 17, 2013 Category: Consumer Health News Source Type: news
Long-Term Treatment With Imatinib Affected Bone Mineral Density
A majority of patients on imatinib for treatment of GIST or CML had low or absent levels of osteocalcin, a bone marker secreted by osteoblasts, and about 50% of patients had a decrease in bone mineral density, signaling that long-term treatment may affect bone health in these patients. (Source: Cancer Network)
Source: Cancer Network - April 15, 2013 Category: Cancer & Oncology Source Type: news
Nilotinib for CML Leads to Fewer Treatment-Emergent Mutations Than Imatinib
CML patients treated with nilotinib had fewer treatment-emergent BCR-ABL mutations than those treated with imatinib, and among patients who did have a mutation, those treated with nilotinib had reduced rates of progression to accelerated phase and blast phase of the disease. (Source: Cancer Network)
Source: Cancer Network - April 12, 2013 Category: Cancer & Oncology Source Type: news
Supreme Court denial of Glivec patent
A decision issued on April 1st by the Indian Supreme Court regarding the Novartis breakthrough medicine Glivec® (imatinib mesylate) provides clarification on Indian patent law and discourages innovative drug discovery essential to advancing medical science for patients. (Source: Pharmacy Europe)
Source: Pharmacy Europe - April 2, 2013 Category: Drugs & Pharmacology Source Type: news
Novartis Loses Its Case to Stop Sale of Generic Gleevec in India
The Indian manufacturer who sells generic version of Gleevec at approximately $175 a dose, a 15-fold lower price than the drug developer Novaris, will be able to continue to sell it according to the India's Supreme Court. Novartis lost its final appeal of the case....Read Full Post (Source: About.com Biotech Biomedical)
Source: About.com Biotech Biomedical - April 1, 2013 Category: Biotechnology Source Type: news
Novartis Loses Landmark India Patent Case on ImatinibNovartis Loses Landmark India Patent Case on Imatinib
India's top court dismissed Swiss drugmaker Novartis AG's attempt to win patent protection for its cancer drug imatinib (Glivec/Gleevec). Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 1, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Novartis Loses In Patent Court Ruling, India
India's Supreme Court turned down Novartis' patent bid for an updated version of Glivec (imatinib mesylate), its blockbusting leukemia medication, saying that the updated compound "did not satisfy the test of novelty or inventiveness" required by the country's legislation. The ruling means that generic drugmakers can continue manufacturing and selling copies of Glivec at low prices. For the last seven years, Swiss pharmaceutical giant Novartis has been fighting a legal battle to gain patent protection for what the company calls an updated version of its top-selling leukemia drug... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 1, 2013 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news
Third Drug Approved for Metastatic, Treatment-Resistant GIST
Regorafenib, a multikinase inhibitor, has been approved as a treatment for locally advanced, unresectable, or metastatic gastrointestinal stromal tumor in people who have been treated with imatinib and... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - March 1, 2013 Category: Cancer & Oncology Source Type: news
Glivec (imatinib) - Novartis Pharmaceuticals UK Limited - revised SPC
Source: eMC (electronic Medicines Compendium)
Area: Other Library Updates > SPC Changes
Section 4.2 Posology and method of administration has been updated to include information with regard to paediatric use. Specifically, it states that there is no experience in children with CML below 2 years of age. There is limited experience in children with Ph+ ALL and very limited experience in children with MDS/MPD, DFSP, GIST and HES/CEL.
The safety and efficacy of imatinib in children with MDS/MPD, DFSP, GIST and HES/CEL aged less than 18 years of age have not been established in clinical trials. Currently availab...
Source: NeLM - SPC Changes - February 28, 2013 Category: Drugs & Pharmacology Source Type: news
FDA Approves Regorafenib (Stivarga) for GIST
The US Food and Drug Administration approved the multi-kinase inhibitor regorafenib (Stivarga) yesterday, for the treatment of patients with unresectable metastatic gastrointestinal stromal tumors (GIST) that no longer respond to imatinib and sunitinib. (Source: Cancer Network)
Source: Cancer Network - February 27, 2013 Category: Cancer & Oncology Source Type: news
Stivarga® (regorafenib) Tablets Approved By U.S. FDA For Treatment Of Patients With Locally Advanced, Unresectable Or Metastatic GIST
Bayer HealthCare and Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) have announced that the U.S. Food and Drug Administration (FDA) approved Bayer's Stivarga® (regorafenib) tablets to treat patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 27, 2013 Category: Consumer Health News Tags: GastroIntestinal / Gastroenterology Source Type: news
